NCT06179108Phase 2Completed

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Study sponsor: LB Pharmaceuticals Inc. · LBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-04Actual
Enrollment · participants359Actual
Source updated2025-10-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview